NRG Oncology
- Country
- ๐บ๐ธUnited States
- Ownership
- Private
- Established
- 2014-01-01
- Employees
- 51
- Market Cap
- -
- Website
- http://www.nrgoncology.org
Five or Ten Year Colonoscopy for 1-2 Non-Advanced Adenomatous Polyps
- Conditions
- Adenocarcinoma of the ColonAdenocarcinoma of the Rectum
- Interventions
- Procedure: 5-year and 10 Year Surveillance Colonoscopy after Qualifying Colonoscopy
- First Posted Date
- 2021-10-18
- Last Posted Date
- 2025-05-04
- Lead Sponsor
- NRG Oncology
- Target Recruit Count
- 9500
- Registration Number
- NCT05080673
- Locations
- ๐บ๐ธ
Fairbanks Memorial Hospital, Fairbanks, Alaska, United States
๐บ๐ธCTCA at Western Regional Medical Center, Goodyear, Arizona, United States
๐บ๐ธKingman Regional Medical Center, Kingman, Arizona, United States
Testing the Addition of the Drug Relugolix to the Usual Radiation Therapy for Advanced-Stage Prostate Cancer, The NRG Promethean Study
- Conditions
- Oligometastatic Prostate CarcinomaProstate AdenocarcinomaProstate Ductal AdenocarcinomaProstate Intraductal CarcinomaStage IVB Prostate Cancer AJCC v8
- Interventions
- Procedure: Biospecimen CollectionProcedure: Bone ScanProcedure: Computed TomographyOther: Fluciclovine F18Procedure: Magnetic Resonance ImagingDrug: Placebo AdministrationProcedure: Positron Emission TomographyProcedure: PSMA PET ScanOther: Quality-of-Life AssessmentRadiation: Stereotactic Body Radiation Therapy
- First Posted Date
- 2021-09-22
- Last Posted Date
- 2025-03-07
- Lead Sponsor
- NRG Oncology
- Target Recruit Count
- 260
- Registration Number
- NCT05053152
- Locations
- ๐บ๐ธ
Cancer Center at Saint Joseph's, Phoenix, Arizona, United States
๐บ๐ธAlta Bates Summit Medical Center-Herrick Campus, Berkeley, California, United States
๐บ๐ธTower Cancer Research Foundation, Beverly Hills, California, United States
Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score, The Guidance Trial
- Conditions
- Prostate Adenocarcinoma
- Interventions
- First Posted Date
- 2021-09-20
- Last Posted Date
- 2025-05-09
- Lead Sponsor
- NRG Oncology
- Target Recruit Count
- 2050
- Registration Number
- NCT05050084
- Locations
- ๐บ๐ธ
University of Alabama at Birmingham Cancer Center, Birmingham, Alabama, United States
๐บ๐ธBanner MD Anderson Cancer Center, Gilbert, Arizona, United States
๐บ๐ธArizona Center for Cancer Care - Gilbert, Gilbert, Arizona, United States
Comparing Cisplatin Every Three Weeks to Cisplatin Weekly When Combined With Radiation for Patients With Advanced Head and Neck Cancer
- Conditions
- Advanced Head and Neck Squamous Cell CarcinomaAdvanced Hypopharyngeal Squamous Cell CarcinomaAdvanced Laryngeal Squamous Cell CarcinomaAdvanced Oropharyngeal Squamous Cell CarcinomaClinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8Stage III Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8Stage III Oropharyngeal (p16-Negative) Carcinoma AJCC v8Stage IV Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8Stage IV Oropharyngeal (p16-Negative) Carcinoma AJCC v8
- Interventions
- Procedure: Computed TomographyProcedure: Magnetic Resonance ImagingProcedure: Positron Emission TomographyOther: Quality-of-Life AssessmentOther: Questionnaire AdministrationRadiation: Radiation Therapy
- First Posted Date
- 2021-09-20
- Last Posted Date
- 2025-05-09
- Lead Sponsor
- NRG Oncology
- Target Recruit Count
- 1714
- Registration Number
- NCT05050162
- Locations
- ๐บ๐ธ
Mobile Infirmary Medical Center, Mobile, Alabama, United States
๐บ๐ธNEA Baptist Memorial Hospital and Fowler Family Cancer Center - Jonesboro, Jonesboro, Arkansas, United States
๐บ๐ธUniversity of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
Testing the Addition of Activity Monitoring With a Wearable Electronic Device to Improve Patient Care During Treatment for Lung Cancer
- Conditions
- Recurrent Non Small Cell Lung CancerNon-small Cell Lung CancerNon-small Cell Lung Cancer Stage III
- Interventions
- Other: Garmin Vivofit Activity Tracker
- First Posted Date
- 2021-05-10
- Last Posted Date
- 2024-01-10
- Lead Sponsor
- NRG Oncology
- Target Recruit Count
- 144
- Registration Number
- NCT04878952
- Locations
- ๐บ๐ธ
WellSpan Health - Ephrata, Ephrata, Pennsylvania, United States
๐บ๐ธWellSpan Health - Chambersburg, Chambersburg, Pennsylvania, United States
๐บ๐ธWellSpan Health - Gettysburg, Gettysburg, Pennsylvania, United States
De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)
- Conditions
- Stage I Breast Cancer
- Interventions
- Other: Radiation and Endocrine Therapy (Tamoxifen, Anastrozol, Letrozole, Exemestane)Drug: Endocrine Therapy (Tamoxifen, Anastrozol, Letrozole, Exemestane)
- First Posted Date
- 2021-04-21
- Last Posted Date
- 2025-05-04
- Lead Sponsor
- NRG Oncology
- Target Recruit Count
- 1670
- Registration Number
- NCT04852887
- Locations
- ๐บ๐ธ
Epic Care-Dublin, Dublin, California, United States
๐บ๐ธUniversity of Alabama at Birmingham Cancer Center, Birmingham, Alabama, United States
๐บ๐ธKingman Regional Medical Center, Kingman, Arizona, United States
Testing if High Dose Radiation Only to the Sites of Brain Cancer Compared to Whole Brain Radiation That Avoids the Hippocampus is Better at Preventing Loss of Memory and Thinking Ability
- Conditions
- Metastatic Lung Small Cell CarcinomaMetastatic Malignant Neoplasm in the BrainRecurrent Lung Small Cell CarcinomaStage IV Lung Cancer AJCC v8
- Interventions
- Procedure: Biospecimen CollectionProcedure: Magnetic Resonance ImagingOther: Neurocognitive AssessmentRadiation: Stereotactic RadiosurgeryRadiation: Whole-Brain Radiotherapy
- First Posted Date
- 2021-03-18
- Last Posted Date
- 2025-05-11
- Lead Sponsor
- NRG Oncology
- Target Recruit Count
- 200
- Registration Number
- NCT04804644
- Locations
- ๐บ๐ธ
Mayo Clinic Hospital in Arizona, Phoenix, Arizona, United States
๐บ๐ธKaiser Permanente-Anaheim, Anaheim, California, United States
๐บ๐ธKaiser Permanente-Bellflower, Bellflower, California, United States
Testing the Addition of Whole Brain Radiotherapy Using a Technique That Avoids the Hippocampus to Stereotactic Radiosurgery in People With Cancer That Has Spread to the Brain and Come Back in Other Areas of the Brain After Earlier Stereotactic Radiosurgery
- Conditions
- Metastatic MelanomaPrognostic Stage IV Breast Cancer AJCC v8Metastatic Digestive System CarcinomaStage IV Renal Cell Cancer AJCC v8Stage IVA Lung Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8Metastatic Breast CarcinomaMetastatic Malignant Neoplasm in the BrainStage IVB Lung Cancer AJCC v8Metastatic Lung Non-Small Cell Carcinoma
- Interventions
- Other: Quality-of-Life AssessmentOther: Questionnaire AdministrationRadiation: Stereotactic RadiosurgeryRadiation: Whole-Brain Radiotherapy
- First Posted Date
- 2020-10-19
- Last Posted Date
- 2024-01-10
- Lead Sponsor
- NRG Oncology
- Target Recruit Count
- 350
- Registration Number
- NCT04588246
- Locations
- ๐บ๐ธ
Banner University Medical Center - Tucson, Tucson, Arizona, United States
๐บ๐ธUniversity of Arizona Cancer Center-North Campus, Tucson, Arizona, United States
๐บ๐ธCity of Hope Corona, Corona, California, United States
Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial
- Conditions
- Prostate AdenocarcinomaStage III Prostate Cancer AJCC v8Stage IVA Prostate Cancer AJCC v8
- Interventions
- Procedure: Biospecimen CollectionProcedure: Bone ScanProcedure: Computed TomographyProcedure: Magnetic Resonance ElastographyProcedure: Positron Emission TomographyOther: Quality-of-Life AssessmentOther: Questionnaire AdministrationRadiation: Radiation Therapy
- First Posted Date
- 2020-08-14
- Last Posted Date
- 2025-05-07
- Lead Sponsor
- NRG Oncology
- Target Recruit Count
- 2753
- Registration Number
- NCT04513717
- Locations
- ๐บ๐ธ
HSHS Sacred Heart Hospital, Eau Claire, Wisconsin, United States
๐บ๐ธCarle Cancer Center, Urbana, Illinois, United States
๐บ๐ธSands Cancer Center, Canandaigua, New York, United States
Testing the Addition of the Anti-cancer Viral Therapy Telomelysinโข to Chemoradiation for Patients With Advanced Esophageal Cancer and Are Not Candidates for Surgery
- Conditions
- Advanced Gastroesophageal Junction AdenocarcinomaPathologic Stage II Esophageal Adenocarcinoma AJCC v8Pathologic Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8Pathologic Stage IIA Esophageal Adenocarcinoma AJCC v8Pathologic Stage IIA Gastroesophageal Junction Adenocarcinoma AJCC v8Pathologic Stage IIB Esophageal Adenocarcinoma AJCC v8Postneoadjuvant Therapy Stage II Esophageal Adenocarcinoma AJCC v8Advanced Esophageal AdenocarcinomaClinical Stage IIA Gastroesophageal Junction Adenocarcinoma AJCC v8Clinical Stage III Esophageal Adenocarcinoma AJCC v8
- Interventions
- Radiation: Radiation TherapyBiological: Telomerase-specific Type 5 Adenovirus OBP-301
- First Posted Date
- 2020-05-18
- Last Posted Date
- 2025-03-07
- Lead Sponsor
- NRG Oncology
- Target Recruit Count
- 16
- Registration Number
- NCT04391049
- Locations
- ๐บ๐ธ
City of Hope Comprehensive Cancer Center, Duarte, California, United States
๐บ๐ธMoffitt Cancer Center, Tampa, Florida, United States
๐บ๐ธCity of Hope South Pasadena, South Pasadena, California, United States